Viking Therapeutics Advances Key Obesity Drug Program with Clinical and Strategic Momentum

Viking Therapeutics is accelerating its efforts in the competitive obesity therapeutics sector. A series of recent developments, spanning clinical data releases, trial recruitment milestones, and a strategic executive appointment, signal the company's progression toward late-stage development. The central question remains whether these operational steps can successfully shepherd its lead candidate, VK2735, to market.

In a move signaling preparation for a potential commercial future, Viking Therapeutics appointed Neil Aubuchon as its new Chief Commercial Officer, effective January 7. Aubuchon brings extensive industry experience from major pharmaceutical firms including Eli Lilly and Amgen. His primary mandate will be to formulate the commercialization strategy for VK2735, indicating the company's expanding focus beyond pure research and development.

Phase 3 Trials Progress Toward Enrollment Goals

The company's pivotal path forward is anchored in the ongoing Phase 3 clinical trials for the subcutaneous formulation of VK2735, a dual GLP-1/GIP receptor agonist. Concrete advances have been reported on two critical studies:

• VANQUISH-1: Patient recruitment is fully complete, with approximately 4,650 participants living with obesity or overweight enrolled.
• VANQUISH-2: This trial focuses on patients with overweight and type 2 diabetes. Viking aims to reach its target of 1,100 participants within the first quarter of 2026.

Both studies are designed to span 78 weeks, with the objective of confirming the long-term safety and efficacy profile of the treatment.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

New Clinical Data and Flexible Dosing Studies

Further evidence supporting the drug candidate's potential was recently published. On January 12, detailed results from the 13-week Phase 2 "VENTURE" study appeared in the medical journal Obesity. The data demonstrated statistically significant weight loss, with a side effect profile characterized predominantly as mild to moderate.

Separately, on January 8, the company announced the completion of enrollment for an exploratory maintenance study. This trial involves roughly 180 participants and is evaluating various dosing regimens following initial weight reduction. The protocols under investigation include monthly injection schedules as well as oral formulations. This administrative flexibility is considered a potentially important factor for long-term patient adherence in a chronic treatment setting.

Investors can expect a comprehensive update on the company's financial position and operational roadmap shortly. Viking Therapeutics is scheduled to release its fourth quarter 2025 results on Wednesday, February 4, 2026.